Want to see RCUS full AI Analyst Report?
RCUS Stock Chart & Stats
$28.42
-$0.58(-2.04%)
At close: 4:00 PM EDT
$28.42
-$0.58(-2.04%)
Day’s Range― - ―
52-Week Range$8.88 - $31.74
Previous Close$27.4
Volume1.27M
Average Volume (3M)1.39M
Market Cap
$3.64B
Enterprise Value$3.30K
Total Cash (Recent Filing)$702.00M
Total Debt (Recent Filing)$114.00M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 10, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.93
Shares Outstanding127,333,374
10 Day Avg. Volume1,023,565
30 Day Avg. Volume1,385,267
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.44Price Target Upside35.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.59
Revenue Forecast (FY)$74.86M
Bulls Say, Bears Say
Bulls Say
Cash Runway And LiquidityA $775M cash position and guidance to end 2026 with roughly $600M, providing runway into at least H2 2028, meaningfully reduces near‑term financing pressure. This durable liquidity allows management to fund registrational trials, multiple INDs and business development without immediate dilution if timelines hold.
Clear Registrational TimelinesDefined milestones for casdatifan (PEAK‑1 enrollment completion and PEAK‑20 start) create a tangible development pathway. Durable value stems from clearer regulatory and commercial planning, enabling prioritized resource allocation, milestone monetization and partnership negotiations tied to concrete timing.
Strategic Collaborations And Scientific ValidationA broad partner network plus translational validation (Nature publication linking biomarker to outcome) strengthens credibility and resource access. Long‑term, collaborations can provide co‑development funding, access to combo regimens, and commercialization pathways that reduce single‑company execution risk.
Bears Say
High And Sustained Cash BurnVery large negative operating and free cash flow (~-$474M TTM) signal persistent burn that will erode reserves absent product revenues. Over multiple quarters this increases dependency on capital markets or partners, raises dilution risk, and constrains strategic flexibility if clinical or regulatory timelines slip.
Volatile And Contracting Revenue BaseRevenue is milestone‑driven and recently contracted ~50% year‑over‑year, reducing predictability and the ability to cover fixed costs. Coupled with expected wind‑down of some collaboration streams, the structural revenue base is weak, making ongoing operations sensitive to a small number of delivery events.
Concentration On Casdatifan (execution Risk)Management plans to concentrate >80% of 2027 R&D spend on casdatifan, materially concentrating resource allocation. This amplifies binary program risk: a negative registrational outcome or safety/regulatory setback for casdatifan would disproportionately impair growth prospects and return on R&D investment.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences’s price range in the past 12 months?
Arcus Biosciences lowest stock price was $8.88 and its highest was $31.73 in the past 12 months.
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $3.64B.
When is Arcus Biosciences’s upcoming earnings report date?
Arcus Biosciences’s upcoming earnings report date is Nov 10, 2026 which is in 90 days.
How were Arcus Biosciences’s earnings last quarter?
Arcus Biosciences released its earnings results on Aug 05, 2026. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.891 by $0.171.
Is Arcus Biosciences overvalued?
According to Wall Street analysts Arcus Biosciences’s price is currently Undervalued.
Does Arcus Biosciences pay dividends?
Arcus Biosciences does not currently pay dividends.
What is Arcus Biosciences’s EPS estimate?
Arcus Biosciences’s EPS estimate is -0.89.
How many shares outstanding does Arcus Biosciences have?
Arcus Biosciences has 127,333,374 shares outstanding.
What happened to Arcus Biosciences’s price movement after its last earnings report?
Arcus Biosciences reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.891. Following the earnings report the stock price went up 2.274%.
Which hedge fund is a major shareholder of Arcus Biosciences?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.44 (35.27% Upside)
$38.44 (35.27% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 394.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
172.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.75%
Trailing 12-Months
Company Description
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS Company Deck
RCUS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple substantial clinical and business positives: strong translational validation (Nature paper), robust development progress for casdatifan with clear registrational timelines (PEAK‑1 enrollment on track and PEAK‑20 planned), multiple strategic collaborations, a broad immunology pipeline with near‑term IND milestones (AB102, TNFR1), and a solid cash runway into H2 2028. Key near‑term risks include a meaningful quarter‑over‑quarter cash reduction (~11.5%), expected declines in collaboration revenue from the Gilead wind‑down, high R&D spend with planned concentration (>80%) on casdatifan by 2027, and dependence on upcoming clinical readouts to validate the growth and revenue thesis. On balance, the highlights — clinical progress, partnerships, translational evidence, and adequate runway — outweigh the lowlights, which are primarily financial/timing and execution risks.View all RCUS earnings summariesRCUS Stock 12 Month Forecast
Average Price Target
$38.44
▲(35.27% Upside)
Technical Analysis
Xencor
―
Crispr Therapeutics AG
―
Legend Biotech
―
Nurix Therapeutics
―
Immunocore Holdings
―
Ownership Overview
4.34% Insiders
14.56% Mutual Funds
26.62% Other Institutional Investors
34.63% Public Companies and
Individual Investors